` HXXB (Idera Pharmaceuticals Inc) vs DAX Index Comparison - Alpha Spread

I
HXXB
vs
D
DAX Index

Over the past 12 months, HXXB has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +31% growth.

Stocks Performance
HXXB vs DAX Index

Loading
HXXB
DAX Index
Add Stock

Performance Gap
HXXB vs DAX Index

Loading
HXXB
DAX Index
Difference
www.alphaspread.com

Performance By Year
HXXB vs DAX Index

Loading
HXXB
DAX Index
Add Stock

Competitors Performance
Idera Pharmaceuticals Inc vs Peers

DAX Index
HXXB
ABBV
AMGN
GILD
VRTX
Add Stock

Idera Pharmaceuticals Inc
Glance View

Market Cap
174.4m EUR
Industry
Biotechnology

Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm designed and is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101.

HXXB Intrinsic Value
Not Available
I
Back to Top